Product Name:
VEGFR2-pY1214
Product Number:
ab-pk133
Target Full Name: Receptor protein-tyrosine kinase vascular endothelial growth factor receptor 2 Tyr-121 phosphosite
Target Alias: A type III receptor tyrosine kinase; CD309; EC 2.7.10.1; FLK1; Kinase insert domain receptor; Protein-tyrosine kinase receptor Flk-1; Vascular endothelial growth factor receptor 2; VEGFR; VEGFR2; VGFR2; VGR2
Product Type Specific: VEGFR2 (KDR; Flk1) protein kinase phosphosite-specific antibody
Antibody Code: PK133
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: Y1214
Protein UniProt: P35968
Protein SigNET: VEGFR2
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Ig Isotype Clone: IgG
Antibody Immunogen Source: Peptide with amino acid sequence surrounding the human VEGFR2 Tyr-1214 phosphosite
Antibody Immunogen Sequence: FH(pY)DN
Antibody Immunogen Description: 5 amino acid phosphopeptide corresponding to the human VEGFR2 Y1214 phosphosite.
Production Method: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02% sodium azide and 50% glycerol
Storage Conditions: -20°C
Storage Stability: > 1 year
Product Use: Western blotting, Immunohistochemistry (IHC)
Antibody Dilution Recommended: 2 µg/mL
Antibody Potency: Very strong
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Rhesus macaque | Rat | Mouse.
Antibody Positive Control: Y1214 phosphorylated VEGFR2
Antibody Specificity: Very high
Antibody Cross Reactivity: No strong cross-reactivities with other proteins.
Related Product 1: VEGFR2-1 pan-specific antibody (Cat. No.: AB-NK245-1)
Related Product 2: VEGFR2-2 pan-specific antibody (Cat. No.: AB-NK245-2)
Related Product 3: VEGFR2-3 pan-specific antibody (Cat. No.: AB-NK245-3)
Related Product 4: VEGFR2-pY1054 phosphosite-specific antibody (Cat. No.: AB-PK852)
Related Product 5: VEGFR1 Y1048 phosphorylation antibody (Cat. No.: AB-PK850)
Related Product 6: VEGFR1 Y1053 phosphorylation antibody (Cat. No.: AB-PK851)
Related Product 7: VEGFR3 Y1068 phosphorylation antibody (Cat. No.: AB-PK853)
Scientific Background: VEGFR2 (KDR, FLK1) is a protein-tyrosine kinase of the TK group and VEGFR (vascular endothelial growth factor receptor) family. It is a receptor kinase that binds VEGFA, VEGFC, and VEGFD, and has an essential function in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. VEGFR2 activation promotes the proliferation, survival, migration, and differentiation of endothelial cells. It is activated by binding VEGF, which induces dimerization and autophosphorylation at the following phosphosites, which all contribute to increased phosphotransferase activity. In addition, autophosphorylation of Y801 induces interaction with PIK3R1, autophosphorylation of Y951 and Y1008 induces interaction with PLCg1, autophosphorylation of Y1054, Y996 and Y1059 induces interaction with PLCg1, and autophosphorylation of Y1175 induces interaction with PLCg1, Shb, Shc1 and Shc2. KDR mediates the activation of the ERK1/2 MAP kinase intracellular signalling pathways. VEGFR2 appears to be an oncoprotein (OP). Mutations in the VEGFR2 gene have been observed in patients with hemangioma. Significantly higher VEGFR2 expression was observed in metastatic as compared to non-metastatic human colon cancer cell lines, which directly correlated with increased neovascularization and tumour cell proliferation. Elevated VEGFR2 expression was also correlated with blood vessel count in human intestinal-type gastric cancers, and in tumour cells in primary and metastatic ovarian carcinomas. VEGF signalling is vital to the early stages of tumour progression in mouse models of squamous skin tumours. In addition, inhibition of VEGFR2 resulted in tumour regression through decreased microvasculature and impaired ability to maintain the stem-like characteristic of the tumour cells. This description may include information annotated by UniProt and/or Google AI.